New agents for hyperkalemia

New England Journal of Medicine

Volumn 372, Issue 16, 2015, Pages 1571-1572

  Packham, David K ^a   Rasmussen, Henrik S ^b   Singh, Bhupinder ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ZS Pharma   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDROCORTISONE; PLACEBO; POLYSTYRENESULFONATE SODIUM; POTASSIUM; SODIUM ZIRCONIUM CYCLOSILICATE; SORBITOL; LOOP DIURETIC AGENT; PATIROMER;

COLON DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; HUMAN; HYPERKALEMIA; INTESTINE NECROSIS; LETTER; OFF LABEL DRUG USE; PHASE 3 CLINICAL TRIAL (TOPIC); POTASSIUM EXCRETION; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUSPENSION; AFRICAN AMERICAN; CHRONIC KIDNEY DISEASE; HYPERTENSION;

EID: 84928039212     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1501933     Document Type: Letter

References (3)

1. Kayexalate. Bridgewater, NJ: Sanofi-Aventis (package insert) (http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 011287s023lbl.pdf).
2. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol 2010;21:733-5.
3. Florinef. Montreal: Paladin Labs (package insert) (http:// www.paladin-labs.com/pdf-files/monograph-florinef.pdf).